Bank of New York Mellon Corp Sells 11,763 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Bank of New York Mellon Corp decreased its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 4.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 252,687 shares of the specialty pharmaceutical company's stock after selling 11,763 shares during the quarter. Bank of New York Mellon Corp owned about 0.78% of Collegium Pharmaceutical worth $7,239,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. TD Private Client Wealth LLC lifted its stake in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company's stock valued at $66,000 after purchasing an additional 483 shares during the last quarter. KBC Group NV raised its stake in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock valued at $67,000 after buying an additional 982 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Collegium Pharmaceutical by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after buying an additional 316 shares during the last quarter. Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical during the 3rd quarter worth approximately $72,000. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Collegium Pharmaceutical by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company's stock worth $196,000 after acquiring an additional 642 shares during the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

COLL has been the subject of several research reports. Needham & Company LLC raised Collegium Pharmaceutical from a "hold" rating to a "buy" rating and set a $46.00 price target for the company in a report on Friday, January 10th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Piper Sandler lowered their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $43.60.

Insider Buying and Selling at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 1,949 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total value of $58,470.00. Following the transaction, the chief financial officer now owns 177,195 shares in the company, valued at approximately $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at $4,330,048.32. This represents a 20.60 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock valued at $3,243,594 in the last three months. Corporate insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Stock Performance

Shares of COLL stock traded down $0.00 on Wednesday, hitting $29.82. The company's stock had a trading volume of 147,575 shares, compared to its average volume of 413,645. Collegium Pharmaceutical, Inc. has a fifty-two week low of $27.28 and a fifty-two week high of $42.29. The company has a market capitalization of $938.88 million, a PE ratio of 12.86 and a beta of 0.99. The stock's 50 day moving average is $30.89 and its 200-day moving average is $32.81. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Equities research analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.